HiFiBiO Therapeutics acquires H-Immune

After already penning two licensing deals in the past few months, HiFiBiO Therapeutics has today announced the acquisition of H-Immune Therapeutics, an early-stage biotechnology company engaged in the discovery and development of novel immuno-oncology therapeutics.

The acquisition strengthens biotech start-up with offices in China, France and the USA HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop diverse antibody therapeutics. Specific financial terms of the transaction were not disclosed.

Established in late 2016 as a spin-out of the French Atomic Energy Commission, H-Immune was founded by Luc Boblet, former co-founder and chief executive of Institute Pasteur spin-out PathoQuest, and Michel Léonetti, senior immunologist.